About

Dr. Kevin Gaddis is an Associate Professor in the Department of Dermatology at the University of Minnesota. He serves as a Staff Dermatologist and Dermatopathologist at the Minneapolis VA Medical Center. His clinical interests include psoriasis, blistering diseases, and dermatopathology. Dr. Gaddis is committed to providing high-quality, high-value medical dermatologic care to his patients. His professional role involves both clinical practice and academic responsibilities within the department.

Research topics

• Medicine
• Dermatology
• Internal medicine
• Pathology
• Oncology

Selected publications

• Cutaneous metastasis of serous ovarian carcinoma

  Dermatology Online Journal · 2025-05-19

  articleOpen accessSenior author

  Ovarian carcinoma ranks among the top causes of cancer-related fatalities among women in the United States [1]. In the spectrum of ovarian carcinomas, low-grade serous ovarian carcinoma (LGSOC) is a relatively rare form, constituting only 2-5% of all ovarian carcinomas [2]. Although metastasis to the peritoneum and other organs is frequently observed, cutaneous metastasis of ovarian carcinoma is uncommon, occurring in less than 4% of cases and occurring even less often in the serous subtype [3]. Owing to its rare and variable presentation, cutaneous involvement in ovarian carcinoma is particularly challenging to recognize. Patients presenting with skin lesions in the setting of a history of ovarian carcinoma should raise suspicion for cutaneous metastasis. We present a rare case of LGSOC with non-nodular cutaneous involvement presenting as asymptomatic erythematous papules and hyperpigmented patches on the upper chest, abdomen, and lower back.

  PublisherOA PDFDOI

• Localized nasal dermatosis in a healthy male

  JAAD Case Reports · 2025-11-08

  articleOpen access
  PublisherDOI

• Comparative histopathologic analysis of COVID-19-associated pseudo-chilblains (“COVID-toes”), with idiopathic pernio, and chilblains lupus erythematosus

  JAAD International · 2025-04-21

  articleOpen access
  PublisherDOI

• Histiocytoid Sweet syndrome-like presentation of mature plasmacytoid dendritic cell proliferation

  Dermatology Online Journal · 2025-06-17

  articleOpen access

  Mature plasmacytoid dendritic cell proliferation is a condition associated with myeloid neoplasms, most commonly chronic myelomonocytic leukemia. Plasmacytoid dendritic cells can resemble lymphocytes and histiocytes morphologically and immunophenotypically. Mature plasmacytoid dendritic cell proliferation may therefore go unrecognized if the diagnosis is not suspected and appropriate stains for plasmacytoid dendritic cells are not performed. Herein, we present a case of mature plasmacytoid dendritic cell proliferation masquerading clinically and histologically as histiocytoid Sweet syndrome. The patient, who had previously been diagnosed with mature plasmacytoid dendritic cell proliferation that presented as pink, edematous, pruritic papules and plaques, had initially resolved following induction chemotherapy for acute myelomonocytic leukemia. However, he presented later with indurated purpuric plaques on the trunk within weeks of receiving filgrastim for neutropenia. Biopsies demonstrated marked dermal edema, interstitial, superficial, and deep infiltrate with histiocytoid appearing cells concerning for histiocytoid Sweet syndrome. Further work-up demonstrated that the infiltrate was predominantly composed of CD3-, CD4+, CD34-, CD123+, CD56-, CD68-, myeloperoxidase negative mononuclear cells consistent with mature plasmacytoid dendritic cell proliferation. This case demonstrates that MPDCP should be considered in the differential diagnosis of eruptions that clinically and histologically look like histiocytoid Sweet syndrome but stain negatively for myeloperoxidase.

  PublisherOA PDFDOI

• Tricky telangiectasias: a pediatric case report and literature review of cutaneous collagenous vasculopathy

  International Journal of Dermatology · 2024-04-10 · 1 citations

  reviewOpen accessSenior author
  PublisherOA PDFDOI

• 399 A novel association of ichthyosis with the GJP2 mutation p.Ser139Asn responsive to ixekizumab therapy

  Journal of Investigative Dermatology · 2024-07-19 · 1 citations

  article
  PublisherDOI

• A case series of hydroxychloroquine exacerbating the dermatomyositis rash

  Dermatology Online Journal · 2023-11-03 · 3 citations

  articleOpen access

  Hydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodies to anti-nuclear matrix protein 2 (NXP2). After discontinuation of HCQ, the time to improvement or resolution of cutaneous symptoms ranged from six weeks to six months. Hydroxychloroquine may be associated with worsening cutaneous features in DM. In patients who are not improving despite escalation of immunosuppressive medications, or are worsening, we recommend a trial of discontinuing HCQ.

  PublisherDOI

• Chronic Crusted Plaque after Skin Injury

  The Journal of Pediatrics · 2023-10-12

  articleOpen access
  PublisherOA PDFDOI

• Cross-sectional study of factors influencing specialty choice among diverse medical students pursuing careers in dermatology

  Journal of the American Academy of Dermatology · 2023-06-19

  article
  PublisherDOI

• Avapritinib-induced photo-aggravated cutaneous reaction

  JAAD Case Reports · 2022-01-06 · 3 citations

  articleOpen access

  Cutaneous phototoxicity is a nonimmunologic reaction resulting in direct cellular damage after sun exposure. This phenomenon occurs secondary to various drugs, including targeted oncologic therapies, in combination with UV-A or visible radiation.1 Currently, tyrosine kinase inhibitors are the treatment of choice for the majority of gastrointestinal stromal tumors (GISTs). Avapritinib, a type I tyrosine kinase inhibitors, was recently approved for patients with GISTs carrying the D842V mutation.2 To date, there is no documented literature on photosensitivity secondary to avapritinib.

  PublisherOA PDFDOI

Frequent coauthors

• Ronda S. Farah

  University of Minnesota

  21 shared

• Laurel L. Wessman

  University Health Care System

  20 shared

• Cindy Firkins Smith

  17 shared

• Adam C. Byrd

  University of Mississippi Medical Center

  16 shared

• Robert T Brodel

  Kandiyohi County Historical Society

  16 shared

• Alexandra Streifel

  Louisiana State University Health Sciences Center New Orleans

  16 shared

• Noah Goldfarb

  University of Minnesota

  9 shared

• Adam I. Rubin

  Hospital of the University of Pennsylvania

  8 shared